About this Research Topic
This Research Topic is part of the Reducing the Harm of Medication – Recent Trends in Pharmacovigilance series (Volume I).
Four years ago, the World Health Organization (WHO) launched the third global health challenge, Medication Without Harm, which set out to achieve a reduction in iatrogenic medication related harm by 50% in 5 years. In this Research Topic, we aim to assess strategies to improve the safety of using medication to achieve this goal.
Medicines are a cornerstone of treatment for many health problems. There are many strategies for reducing adverse drug events (ADEs): labelling medications and solutions in hospitals, reconciling medication, improving prescription, and patient self-management skills education and training. However, research in the area is poorly organized among diseases, populations and environments. There are few strategies to help recognize that an ADE is caused by the drug, that is, if it is an adverse drug reaction (ADR). This can make it difficult for policymakers, health professionals, and others to find and use the evidence on how to address ADRs. In a pandemic situation where the most vulnerable patients are certain special populations (for example, the elderly) and patients with coexisting underlying diseases, the treatment of a new disease may conflict with existing treatment. Therefore, possibly now even more than before, the timely and accurate identification of ADRs is needed to improve results. The quality of data needs to be strengthened in order to:
• monitor medication-related harm, to improve medication safety through improved packaging and labelling
• evaluate the pharmacy benefit design to improve adherence to treatment and reduce self-medication
• evaluate the tools and technologies that empower patients to safety manage their own medications
• evaluate the impact of the strategies to reduce the harm of medication
• monitor the impact of COVID-19 treatments, including vaccines, on the population, with an emphasis on the most vulnerable, the elderly, children and pregnant women
The aim of this Research Topic is to assemble review articles and original research of ADE early detection, identification of the culprit drug and treatment strategies. ADE/ADR reporting programs around the world are collected. Strategies in preventing ADEs are very welcome. Preliminary opinions on the safety of the treatments currently used to treat patients with COVID-19 are also welcome.
Keywords: adverse drug effect, medication without harm, pharmacovigilance, pharmacoepidemiology, causality assessment method, causality algorithm
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.